IN2012DN00042A - - Google Patents
Info
- Publication number
- IN2012DN00042A IN2012DN00042A IN42DEN2012A IN2012DN00042A IN 2012DN00042 A IN2012DN00042 A IN 2012DN00042A IN 42DEN2012 A IN42DEN2012 A IN 42DEN2012A IN 2012DN00042 A IN2012DN00042 A IN 2012DN00042A
- Authority
- IN
- India
- Prior art keywords
- multidrug resistant
- antibiotic
- bacterium
- resistant bacterium
- provides
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 abstract 6
- 230000003115 biocidal effect Effects 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 abstract 2
- 229940072056 alginate Drugs 0.000 abstract 2
- 235000010443 alginic acid Nutrition 0.000 abstract 2
- 229920000615 alginic acid Polymers 0.000 abstract 2
- 238000004140 cleaning Methods 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
- A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
- A01N43/22—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom rings with more than six members
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/60—1,4-Diazines; Hydrogenated 1,4-diazines
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/86—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms six-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
Abstract
The invention provides a method of overcoming resistance to at least one antibiotic in a multidrug resistant bacterium, said method comprising contacting said bacterium with an alginate oligomer together with the antibiotic. The multidrug resistant bacterium may be on an animate or inanimate surface and both medical and nonmedical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium to overcome resistance to the antibiotic in said multidrug resistant bacterium. In another aspect the method can be used to combat contamination of a site with multidrug resistant bacteria, e.g. for disinfection and cleaning purposes.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0909557A GB0909557D0 (en) | 2009-06-03 | 2009-06-03 | Anti-microbial alginate oligomers |
GB0913829A GB0913829D0 (en) | 2009-08-07 | 2009-08-07 | Treatment of acinetobacter with alginate oligomers and macrolide antibiotics |
GB0917995A GB0917995D0 (en) | 2009-10-14 | 2009-10-14 | Alginate oligomers for use in overcoming multidrug resistance in bacteria |
PCT/GB2010/001097 WO2010139957A1 (en) | 2009-06-03 | 2010-06-03 | Alginate oligomers for use in overcoming multidrug resistance in bacteria |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN00042A true IN2012DN00042A (en) | 2015-04-03 |
Family
ID=42314813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN42DEN2012 IN2012DN00042A (en) | 2009-06-03 | 2010-06-03 |
Country Status (18)
Country | Link |
---|---|
US (3) | US8815831B2 (en) |
EP (2) | EP2437783B1 (en) |
JP (2) | JP5202764B2 (en) |
KR (2) | KR101758668B1 (en) |
CN (2) | CN102497883B (en) |
AU (2) | AU2010255542B2 (en) |
BR (2) | BRPI1011248A2 (en) |
CA (2) | CA2764195C (en) |
DK (2) | DK2437783T3 (en) |
ES (2) | ES2442793T3 (en) |
GB (2) | GB2483203B (en) |
IN (1) | IN2012DN00042A (en) |
PL (2) | PL2437784T3 (en) |
PT (2) | PT2437783E (en) |
RS (2) | RS53136B (en) |
RU (4) | RU2586253C2 (en) |
SI (2) | SI2437784T1 (en) |
WO (2) | WO2010139957A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11672818B2 (en) | 2018-03-06 | 2023-06-13 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
US11697693B2 (en) | 2017-01-03 | 2023-07-11 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101917850B (en) | 2007-10-25 | 2016-01-13 | 森普拉制药公司 | The preparation method of macrolide antibacterial agents |
CA2706637C (en) * | 2007-11-27 | 2016-11-29 | Algipharma Ipr As | Use of alginate oligomers in combating biofilms |
CN102344898B (en) * | 2011-10-19 | 2013-03-13 | 黑龙江大学 | Klebsiella variicola strain |
US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
KR20140139083A (en) | 2012-03-27 | 2014-12-04 | 셈프라 파마슈티컬스, 인크. | Parenteral formulations for administering macrolide antibiotics |
KR101438969B1 (en) * | 2012-12-27 | 2014-09-11 | 현대자동차주식회사 | Pseudomonas nitroreducens for Odorless Bioflim-Coated Evaporator Core and uses thereof |
US9993497B2 (en) | 2012-12-30 | 2018-06-12 | Hadasit Medical Research Services And Development Ltd. | Use of alginate compositions in preventing or reducing liver damage caused by a hepatotoxic agent |
JP2016521752A (en) * | 2013-06-13 | 2016-07-25 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Compositions and methods for the treatment of Burkholderia infections |
KR101502773B1 (en) * | 2013-07-25 | 2015-03-24 | 조선대학교산학협력단 | A novel bifunctional peptide and its use with antimicrobial activity and anti inflammatory action from Bacillus strain |
GB201322777D0 (en) | 2013-12-20 | 2014-02-05 | Algipharma As | Use of alginate oligomers as blood anticoagulants |
EP3110426A1 (en) * | 2014-02-28 | 2017-01-04 | Algipharma As | Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function |
GB201415381D0 (en) * | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
GB201504878D0 (en) | 2015-03-23 | 2015-05-06 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
JP2017055716A (en) * | 2015-09-17 | 2017-03-23 | 国立大学法人名古屋大学 | Plate for screening multidrug-resistant bacteria, method for detecting multidrug-resistant bacteria, kit for detecting multidrug-resistant bacteria, and liquid medium for screening multidrug-resistant bacteria |
GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
WO2017066719A2 (en) | 2015-10-14 | 2017-04-20 | Research Institute At Nationwide Children's Hospital | Hu specific interfering agents |
RU2631106C1 (en) * | 2016-05-06 | 2017-09-18 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Method for removable prostheses manufacture |
US10201518B2 (en) | 2016-09-28 | 2019-02-12 | The University Of Hong Kong | Bismuth(III) compounds and methods thereof |
GB2555391B (en) * | 2016-10-21 | 2019-06-26 | Algipharma As | Bacitracin-alginate oligomer conjugates |
KR20190072579A (en) * | 2016-10-21 | 2019-06-25 | 알지파마 에이에스 | Polymyxin-Alginate Oligomer Conjugate |
EP3592364A1 (en) * | 2017-03-07 | 2020-01-15 | Cempra Pharmaceuticals, Inc. | Compositions and methods for treating dry eye diseases |
EP3600338A4 (en) | 2017-03-28 | 2020-10-28 | The University of North Carolina at Chapel Hill | Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto |
FR3072246B1 (en) * | 2017-10-13 | 2020-06-12 | Biodesiv Efnium | ANTIMICROBIAL POLYMER FOR ANIMAL SEEDS |
CN108948005A (en) * | 2018-07-03 | 2018-12-07 | 湖南华腾制药有限公司 | Polyethyleneglycol modified Enoxacin and application |
GB201812473D0 (en) | 2018-07-31 | 2018-09-12 | Algipharma As | Method for the qualitative and quantitative detection of alginate oligomers in body fluids |
CN108863618A (en) * | 2018-09-19 | 2018-11-23 | 贵州大学 | A kind of tea tree selenium-rich liquid bacterial manure and the preparation method and application thereof |
CA3124673A1 (en) | 2018-12-28 | 2020-07-02 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto |
CN111218464A (en) * | 2019-07-01 | 2020-06-02 | 中国科学院海洋研究所 | Kelp mannuronic acid C5-isomerase gene and application thereof |
CN110499353B (en) * | 2019-08-09 | 2023-11-07 | 佛山市第四人民医院(佛山市结核病防治所) | Microbial marker for tuberculosis drug resistance diagnosis and application thereof |
CN111172144A (en) * | 2019-12-27 | 2020-05-19 | 华南农业大学 | Microbial agent for efficiently degrading tetracycline antibiotics and application of microbial agent in soil pollution remediation |
WO2022147148A1 (en) * | 2020-12-30 | 2022-07-07 | Trellis Bioscience, Inc. | Therapeutic protein formulations comprising anti-dnabii antibodies and uses thereof |
CN114410693B (en) * | 2021-12-08 | 2023-08-04 | 中南大学 | Biological iron-manganese oxide, preparation method thereof and application thereof in simultaneous removal of arsenic and antimony in wastewater |
WO2023129726A2 (en) * | 2021-12-30 | 2023-07-06 | Sigilon Therapeutics, Inc. | Modified polysaccharide polymers and related compositions and methods thereof |
CN114349174B (en) * | 2022-01-17 | 2022-10-04 | 大连理工大学 | Method for removing tetracycline based on algae-bacteria complex |
CN117185499B (en) * | 2023-11-08 | 2024-01-30 | 北京大学 | Synechocystis PCC 6803 capable of tolerating sulfonamide antibiotics and application thereof |
CN117838672B (en) * | 2024-03-07 | 2024-05-10 | 山东第二医科大学 | Tilmicosin/G-type brown alginate oligosaccharide aerosol inhalation nanometer suspension and preparation method thereof |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL297511A (en) | 1956-12-20 | |||
FR7576M (en) | 1968-03-27 | 1970-01-05 | ||
HU172831B (en) | 1976-03-31 | 1978-12-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing complex compounds of oligo- and polygalacturonic acids with essential metal ions |
NZ196348A (en) * | 1980-03-07 | 1984-08-24 | Interx Research Corp | Enhancement of absorption rate of orally administered antibiotics |
DD268865A1 (en) | 1987-01-16 | 1989-06-14 | Adw Ddr | PROCESS FOR PREPARING A PHARMACEUTICAL PREPARATORY |
US4898852A (en) | 1987-06-02 | 1990-02-06 | Walsh William E | Cyclopolgalcturonic acid composition and treatment |
US4855128A (en) | 1988-01-14 | 1989-08-08 | Warner-Lambert Company | Saccharide inhibition of dental plaque |
GB8803157D0 (en) | 1988-02-11 | 1988-03-09 | Nat Res Dev | Denture protection |
WO1991011205A1 (en) | 1990-01-23 | 1991-08-08 | Trancel Corporation | Mannuronic acid containing alginate wound healing composition and method |
US5169840A (en) | 1991-03-27 | 1992-12-08 | Nobipols Forskningsstiftelse | Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation |
US5166137A (en) | 1991-03-27 | 1992-11-24 | Nobipols Forskningsstiftelse | Guluronic acid polymers and use of same for inhibition of cytokine production |
JPH05252970A (en) | 1991-10-04 | 1993-10-05 | Maruha Corp | Production of alginic acid oligosaccharide having bacteriostatic action and bacteriostatic agent containing the substance as active component |
CA2106609A1 (en) | 1992-09-28 | 1994-03-29 | Irene Yeatman Aldridge | Proteases to inhibit and remove biofilm |
GB9221163D0 (en) | 1992-10-08 | 1992-11-25 | Nobipol And Protan Biopolymer | Dna compounds |
DE4330773A1 (en) | 1993-09-10 | 1995-03-16 | Laevosan Gmbh & Co Kg | Blocking the attachment of germs to human cells |
AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
DE69637625D1 (en) | 1995-10-19 | 2008-09-18 | Bio Origyn Llc | METHODS AND COMPOSITIONS THAT IMPROVE THE SURVIVAL AND FUNCTION OF GERMAN CELLS AND EMBRYOS |
JP3512553B2 (en) | 1996-01-30 | 2004-03-29 | ポーラ化成工業株式会社 | Constipation inhibitor and composition containing it |
NO305441B1 (en) | 1996-07-12 | 1999-05-31 | Norsk Hydro As | Use of G-block polysaccharides |
CN1197584C (en) | 1997-04-30 | 2005-04-20 | 雷克特本克斯尔保健(英国)有限公司 | Pourable alginate compositions |
NO305033B1 (en) | 1997-05-09 | 1999-03-22 | Algipharma As | Process for the preparation of uric acid blocks from alginate |
GB2325233B (en) | 1997-05-16 | 2001-07-18 | Norsk Hydro As | Substrates having bound polysaccharides and bacterial nucleic acids |
US6339075B1 (en) | 1997-06-30 | 2002-01-15 | The University Of British Columbia | Use of dextran and other polysaccharides to improve mucus clearance |
KR100322511B1 (en) | 1998-11-13 | 2002-10-25 | 한국해양연구원 | Red tide remover and remedy for disease of fishes using alginate polygalacturonite oligomer derivatives |
US20040224922A1 (en) | 1999-08-26 | 2004-11-11 | Malcolm King | Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
EP1212047A2 (en) | 1999-08-26 | 2002-06-12 | The Governors Of The University Of Alberta | Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
AU7434200A (en) | 1999-09-23 | 2001-04-24 | Reckitt Benckiser (Uk) Limited | Method for combating hard water and scale by using algins |
RU2167654C1 (en) * | 2000-02-15 | 2001-05-27 | Башкирский государственный университет | Method of enhancement of antibiotic therapy effectiveness |
DE10006989A1 (en) | 2000-02-16 | 2001-08-23 | Nutricia Nv | Pharmaceutical or dietetic preparation for preventing cellular adhesion of pathogens, e.g. in treatment of infections, comprising carbohydrate having double bond-containing terminal uronic acid unit |
RU2274442C2 (en) | 2000-03-07 | 2006-04-20 | Раш-Презбитериан-Ст. Лук'С Медикал Сентер | Compositions and methods for entrapping and inactivation of pathogenic microorganisms and spermatozoids |
GB0005743D0 (en) | 2000-03-10 | 2000-05-03 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions including alginates |
DE10019076A1 (en) | 2000-04-06 | 2001-10-18 | Lang Christine | Use of polygalacturonides as food additives |
IL156596A0 (en) | 2000-12-27 | 2004-01-04 | Salus Pharma Inc | Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections |
ITMI20010347A1 (en) | 2001-02-21 | 2002-08-21 | Grisotech S A | IMMUNOGLOBULIN AND POLYSACCHARID COMPLEXES FOR ORAL ABSORPTION ETRANS-MUCOSAL |
US7494669B2 (en) | 2001-02-28 | 2009-02-24 | Carrington Laboratories, Inc. | Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
NO324131B1 (en) | 2001-11-30 | 2007-09-03 | Fmc Biopolymer As | Process for the preparation of alginate having a high mannuronic acid content |
NO326145B1 (en) | 2001-11-30 | 2008-10-06 | Fmc Biopolymer As | Method of stimulating weight gain in mammals, birds and reptiles. |
US6610331B1 (en) | 2002-05-30 | 2003-08-26 | Scott M. Sweazy | Fertility kit |
NO20023581D0 (en) | 2002-07-26 | 2002-07-26 | Fmc Biopolymer As | New mutant strains of Pseudomonas fluorescence and variants thereof, methods of production and use thereof for the production of alginate |
GB0300597D0 (en) | 2003-01-10 | 2003-02-12 | Microbiological Res Authority | Phage biofilms |
DE602004025824D1 (en) | 2003-09-08 | 2010-04-15 | Fmc Biopolymer As | GEL FOAM ON BIOPOLYMER BASE |
JP2005145885A (en) | 2003-11-14 | 2005-06-09 | Japan Science & Technology Agency | Immunologic mechanism activator comprising alginic acid oligomer |
CN101001635A (en) | 2003-12-04 | 2007-07-18 | 生物膜策略公司 | Methods and compositions for preventing biofilm formation, reducing existing biofilms, and for reducing populations of bacteria |
JP5367266B2 (en) | 2004-10-12 | 2013-12-11 | エフエムシー バイオポリマー エイエス | Self-gelling alginate system and use thereof |
EP1714660A1 (en) | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronic acid and probiotics |
EP1879589A2 (en) * | 2005-05-13 | 2008-01-23 | Venus Remedies Limited | Treatment and control of severe infections including cystic fibrosis |
EP1745705A1 (en) | 2005-07-20 | 2007-01-24 | N.V. Nutricia | Process for preparing uronic acid oligosaccharides by extrusion |
GB2430881B (en) | 2005-10-06 | 2010-10-13 | Ntnu Technology Transfer As | Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity |
JP5248492B2 (en) | 2006-07-14 | 2013-07-31 | エフエムシー バイオポリマー エイエス | Hydrogels containing low molecular weight alginate and biostructures made therefrom |
DE102006059510A1 (en) | 2006-12-14 | 2008-06-19 | Grünenthal GmbH | Coated pellets |
WO2008082948A2 (en) | 2006-12-29 | 2008-07-10 | Bausch & Lomb Incorporated | Ophthalmic alginate composition related methods of manufacture and methods of use |
GB0707096D0 (en) | 2007-04-12 | 2007-05-23 | Ntnu Technology Transfer As | Method |
JP2008285431A (en) | 2007-05-16 | 2008-11-27 | Japan Science & Technology Agency | Composition for preventing and treating viral infectious disease of cultured fish |
US20090036554A1 (en) | 2007-08-01 | 2009-02-05 | Burke Susan E | Ophthalmic compositions comprising a terpene compound |
US20090036404A1 (en) | 2007-08-02 | 2009-02-05 | Macleod Steven K | Ophthalmic compositions comprising a carboxyl-modified fructan or a salt thereof |
CA2706637C (en) * | 2007-11-27 | 2016-11-29 | Algipharma Ipr As | Use of alginate oligomers in combating biofilms |
-
2010
- 2010-06-03 PT PT10722755T patent/PT2437783E/en unknown
- 2010-06-03 EP EP20100722755 patent/EP2437783B1/en active Active
- 2010-06-03 RU RU2011148758/15A patent/RU2586253C2/en active
- 2010-06-03 RU RU2011148757/15A patent/RU2582938C2/en active IP Right Revival
- 2010-06-03 EP EP20100722756 patent/EP2437784B8/en active Active
- 2010-06-03 RU RU2016109404A patent/RU2016109404A/en not_active Application Discontinuation
- 2010-06-03 RS RSP20140013 patent/RS53136B/en unknown
- 2010-06-03 SI SI201030504T patent/SI2437784T1/en unknown
- 2010-06-03 KR KR1020117031426A patent/KR101758668B1/en active IP Right Grant
- 2010-06-03 WO PCT/GB2010/001097 patent/WO2010139957A1/en active Application Filing
- 2010-06-03 IN IN42DEN2012 patent/IN2012DN00042A/en unknown
- 2010-06-03 DK DK10722755T patent/DK2437783T3/en active
- 2010-06-03 BR BRPI1011248A patent/BRPI1011248A2/en not_active Application Discontinuation
- 2010-06-03 CN CN201080034492.6A patent/CN102497883B/en active Active
- 2010-06-03 GB GB201122180A patent/GB2483203B/en active Active
- 2010-06-03 CN CN201080034364.1A patent/CN102458474B/en active Active
- 2010-06-03 DK DK10722756T patent/DK2437784T3/en active
- 2010-06-03 PL PL10722756T patent/PL2437784T3/en unknown
- 2010-06-03 KR KR1020117031452A patent/KR101754691B1/en not_active Application Discontinuation
- 2010-06-03 ES ES10722755T patent/ES2442793T3/en active Active
- 2010-06-03 CA CA2764195A patent/CA2764195C/en active Active
- 2010-06-03 BR BRPI1010780-0A patent/BRPI1010780A2/en not_active Application Discontinuation
- 2010-06-03 RU RU2016109403A patent/RU2016109403A/en not_active Application Discontinuation
- 2010-06-03 ES ES10722756T patent/ES2444541T3/en active Active
- 2010-06-03 US US13/376,140 patent/US8815831B2/en active Active
- 2010-06-03 PL PL10722755T patent/PL2437783T3/en unknown
- 2010-06-03 SI SI201030493T patent/SI2437783T1/en unknown
- 2010-06-03 AU AU2010255542A patent/AU2010255542B2/en active Active
- 2010-06-03 GB GB201122175A patent/GB2483413B/en active Active
- 2010-06-03 JP JP2012513675A patent/JP5202764B2/en active Active
- 2010-06-03 JP JP2012513674A patent/JP5202763B2/en active Active
- 2010-06-03 WO PCT/GB2010/001096 patent/WO2010139956A1/en active Application Filing
- 2010-06-03 AU AU2010255543A patent/AU2010255543B2/en active Active
- 2010-06-03 PT PT10722756T patent/PT2437784E/en unknown
- 2010-06-03 US US13/376,164 patent/US9018158B2/en active Active
- 2010-06-03 RS RSP20140030 patent/RS53139B/en unknown
- 2010-06-03 CA CA2764197A patent/CA2764197C/en active Active
-
2015
- 2015-04-27 US US14/697,522 patent/US9801901B2/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11697693B2 (en) | 2017-01-03 | 2023-07-11 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
US11672818B2 (en) | 2018-03-06 | 2023-06-13 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN00042A (en) | ||
WO2009068841A8 (en) | Use of alginate oligomers in combating biofilms | |
WO2012054589A3 (en) | Conduit-containing devices and methods for analyte processing and detection | |
EP2240109A4 (en) | Systems and methods for tissue examination, diagnostic, treatment, and/or monitoring | |
BRPI0906975A2 (en) | Toothbrush for the treatment and / or detection of microbes. | |
BRPI0923870A2 (en) | Multiple source transmission system and instant messaging file method. | |
TN2010000137A1 (en) | Spiropyrrolidines and their use against hcv and hiv infection | |
WO2012054638A3 (en) | Nmr systems and methods for the detection of analytes | |
EP2040720A4 (en) | Method for the detection and neutralization of bacteria | |
BRPI1007996A2 (en) | treatment fluid and method | |
EP2030636A3 (en) | Self-sterilizing device | |
BRPI0922752A2 (en) | tissue removal device and system. | |
HK1163151A1 (en) | Device for cultivating algae and or microorganisms for treating an effluent, and biological frontage | |
BRPI0910686A2 (en) | genetically modified human umbilical cord perivascular cells for the prophylaxis against or treatment of biological and chemical agents. | |
GB201015717D0 (en) | Apparatus for gripping a chain | |
WO2012058456A3 (en) | Method and apparatus for disinfecting and/or self-sterilizing a stethoscope using plasma energy | |
BRPI0917331A2 (en) | immunogenic molecule, composition, method of treating or preventing a condition caused or associated with plasmodium falciparum infection and screening for the presence of an antibody inhibiting plasmodium falciparum invasion in a patient; and, use of an immunogenic molecule and a composition | |
WO2010100632A3 (en) | Chlamydia antigens | |
WO2010134827A9 (en) | Extended acting oxygen generating composition for treating microbial infections | |
EP2538970A4 (en) | Treatment or prevention of infection | |
BR112012003469A2 (en) | "device and method of preconcentration. | |
WO2008097364A3 (en) | Use of oritavancin for prevention and treatment of anthrax | |
MX2009009693A (en) | Methods of activating irs-1 and akt. | |
PL385415A1 (en) | Method of bacterial resistance detection, diagnostic kit and application of the determination of presencea of the drug and/or products of its decomposition | |
EP2550013A4 (en) | Treating allergy with detoxified e. coli heat-labile enterotoxin |